TY - JOUR
AB - Editor Vivian Fonseca, MD Division of Endocrinology, Tulane University Medical Center, 1430 Tulane Avenue (SL 53), New Orleans, LA 70112, USA. E-mail: vfonseca@tulane.edu Tan MH, Johns D, Strand J, et al.: Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes. Diabet Med 2004, 21:859–866. Significance: Progression of 
-cell failure leads to loss of efficacy of diabetes medications over time, particularly with sulfonylureas and metformin. Preliminary data from extension studies of short- term clinical trials suggest that thiazolidinediones may improve 
-cell function sufficiently so that they may maintain efficacy long term. These data suggest that the effects of pioglitazone are more sustained than those of glibenclamide for improving insulin sensitivity in patients with type 2 dia- betes, and that 52 weeks of treatment with pioglitazone has favorable effects on glycemic control and lipoprotein profile. Findings: Patients with type 2 diabetes were randomized to receive either pioglitazone (initially 30 mg/ d, n = 91) or micronized glibenclamide (initially 1.75 mg/d, n = 109) as monotherapy. Doses were titrated (to 45 mg for pioglitazone and 10.5 mg for glibenclamide) to achieve glycemic targets during the next 12 weeks: fasting blood glucose 
TI - Literatuer alert
JF - Current Diabetes Reports
DO - 10.1007/s11892-004-0045-1
DA - 2004-05-15
UR - https://www.deepdyve.com/lp/springer-journals/literatuer-alert-PCu05wUkxA
SP - 399
EP - 400
VL - 4
IS - 6
DP - DeepDyve
ER -